Background Cerebral cavernous malformations (CCMs) are prone to bleeding but the risk of intracranial haemorrhage and focal neurological defi cits, and the factors that might predict their occurrence, are unclear. We aimed to quantify these risks and investigate whether they are aff ected by sex and CCM location.
Introduction
Cerebral cavernous malformations (CCMs) are common, occurring in one in about 600 neurologically asymptomatic people as evident on MRI scans and one in about 200 patients in hospital-based MRI or autopsy series. [1] [2] [3] [4] [5] Population-based annual CCM detection rates were 0·17 (95% CI 0·00-0·34) per 100 000 people in the USA from 1965 to 1992 compared with 0·56 (0·41-0·75) per 100 000 in Scotland from 1999 to 2000; 6, 7 this diff erence in detection rates might be partly explained by the increasing availability and use of brain MRI. CCMs can be sporadic or inherited as an autosomal dominant trait, 8 in which multiple CCMs occur, and appear de novo. 9 CCMs are blood vessels devoid of muscular and elastic tissue that are lined with endothelial cells that do not have intervening tight junctions. CCMs are prone to haemorrhage, 10 which results in distinctive diagnostic appearances on pathological examination and MRI. [10] [11] [12] Of CCMs diag nosed in adults on the basis of neurological symptoms, one quarter are identifi ed owing to intracranial haemor rhage and another quarter are identifi ed after a focal neurological defi cit without radiographic evidence of recent haemorrhage; 13 the remainder of patients present with epileptic seizures. 14 Hospital-based case series have described the untreated clinical course of CCMs during mostly retrospective observation, with means of 1·9-5·2 years follow-up. In these studies, inception points (ie, the start of followup), diagnostic criteria, outcome defi nitions, and methods of assessment and analysis varied (fi gure 1 and webappendix pp 1-3). 3, 5, 12, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In these studies, the annual risk of fi rst intracranial haemorrhage (range 0·4-0·6%) 16, 17 and the annual risk of recurrent intracranial haemorrhage (3·8-22·9%) 3, 16, 17, 21 varied (fi gure 1). Patients with brainstem CCM seem to have a higher risk of recurrent intracranial haemorrhage when indirectly compared with cohorts of patients with CCM in other brain regions (21·0-60·2%; fi gure 1), 15, 20, 22, 24 although internal comparisons within individual cohorts have not confi rmed this fi nding. 17, 21 Findings have not been consistent regarding whether female sex is associated with incident haemorrhage 5, 16 or not, 19 or with recurrent intracranial haemorrhage 16, 19 or not. 17, 18, 21 Intracranial haemorrhage from a CCM tends to be intracerebral and of low volume, 26 although case fatality has ranged from 0% overall 18 to 17% for recurrent haemorrhage from brainstem CCMs. 15 Little is known about the eff ect of intracranial haemorrhage or nonhaemorrhagic focal neurological defi cits on survivors' functional outcome. 18, 27, 28 Therefore, we investigated the risks, predictors, and functional eff ect of intracranial haemorrhage and nonhaemorrhagic focal neurological defi cits in a prospective, population-based cohort study. We planned to report outcomes at 5 years to encourage standardisation of outcome reporting for CCMs, 13 and we aimed to stratify survival analyses by mode of initial CCM presentation. We hypothesised that female sex and brainstem CCM location would also predict poor outcome.
Methods

Patients
The Scottish Audit of Intracranial Vascular Malformations (SAIVMs) is an ongoing National Health Service clinical audit of adults who were aged 16 years or older and were resident in Scotland when fi rst diagnosed with any type of intracranial vascular malformation during 1999-2003 and 2006-2010. The Scottish Intracranial Vascular Malformations Study (SIVMS) is a prospective, population-based cohort study in which we used anonymous data extracts from SAIVMs. We have published the audit protocol and registered the research protocol with the Directory of Clinical Databases (DoCDat). Patients were identifi ed through multiple overlapping sources of case ascertain ment, which included a Scotland-wide collaborative network of neurologists, neurosurgeons, stroke physicians, radiologists, and pathologists and central registers of hospital discharge records and death certifi cates. 7 In this analysis, we included every adult in SIVMS who had a fi rst-in-alifetime defi nite diagnosis of CCM in the years 1999-2003, made on the basis of pathological examination or brain MRI. 11, 12 The Multicentre Research Ethics Committee for Scotland (MREC/98/0/48) and the Fife and Forth Valley Research Ethics Committee (08/S0501/76) approved the under taking of observational studies (to which an opt-out consent policy applied) and postal questionnaire studies (which required opt-in consent).
Procedures
The inception point was an adult's initial presentation, which was the date of symptom onset or medical consultation (if asymptomatic) that led to an investigation that diagnosed a CCM. We used annual surveillance of family doctor and hospital medical records, as well as annual postal questionnaires to family doctors and consenting participants with a CCM on each anniversary of CCM diagnosis, to establish demographics and medical histories, to identify outcome events, and to assess adults' dependence (by the Oxford Handicap Scale [OHS]) prospectively during follow-up. 29 Two neuroradiologists (JJB and RJS) used the diagnostic brain images that had been obtained in clinical practice to verify CCM diagnosis with reference to accepted criteria 11, 12 and collected data on CCM anatomical location, CCM size, coexistent intracranial vascular malformations, and radiological evidence for recent intracranial haemorrhage. 13 We also reviewed brain imaging and reports of pathological examinations to classify the mode of initial CCM presentation. Two investigators (CPW and RA-SS) assessed outcome events using the clinical, radiological, and pathological information available, masked to sex and CCM location. To attribute the mode and cause of death, we reviewed death certifi cates, autopsy reports if post-mortem examination had been done, and clinical records and pertinent brain images if death had occurred during a hospital stay.
We used published criteria to distinguish intracranial haemorrhage, non-haemorrhagic focal neurological deficits (if timely brain imaging of the appropriate modality had not identifi ed fresh haemorrhage), and focal neurological defi cits not otherwise specifi ed (if timely brain imaging of the appropriate modality had not been done). 13 We regarded initial presentations as incidental if the adult had been asymptomatic or if their symptoms For the DoCDat see http://www. icapp.nhs.uk/docdat/ (eg, headache) could not be related to the underlying CCM. We attributed initial presentations to epileptic seizures if the seizures were not symptomatic of a concomitant intracranial haemorrhage. When assessing clinical events at initial presentation and during followup, we also classifi ed whether they were defi nitely, possibly, or defi nitely not attributable to the CCM. We classifi ed events as possibly attributable to a CCM when the clinical features of an event were anatomically consistent with CCM location, but another cause (eg, ischaemic stroke) was possible and neuroradiological investigation had not identifi ed either CCM haemorrhage or an alternative cause. The primary outcome was a composite of intracranial haemorrhage or focal neurological defi cit because their severities seem to be similar 26 and many focal neurological defi cits might be haemorrhages undetected by imaging. 13 We quantifi ed intracranial haemorrhage alone to facilitate comparison with other studies, but chose a composite primary outcome to show all the neurological defi cits experienced by patients. The primary outcome combined events defi nitely attributable to a CCM with those possibly attributable because of the absence of a better alternative explanation. 13 We have described the occurrence of seizures after a diagnosis of CCM in this cohort elsewhere. 14
Statistical analysis
We categorised CCM location as brainstem (in the midbrain, pons, or medulla), cerebellar, deep (in the thalamus or basal ganglia), or lobar (in the cortex or subcortical areas of the cerebral hemispheres). We dichotomised location into brainstem versus other locations for univariate analyses; if an adult had many CCMs, we allocated a primary location according to the location of the symptomatic CCM, but in asymptomatic adults the brainstem CCM location took precedence because it was postulated to be a predictor of intracranial haemorrhage or focal neuro logical defi cit. We used parametric statistics for between-group comparisons when the data obeyed a normal distribution and nonparametric statistics when they did not. We used exact tests when cell counts were fewer than fi ve.
We quantifi ed completeness of the follow-up data we had accrued as a proportion of all the follow-up that could have been obtained before death or the end of the 5-year timeframe for these analyses. 30 We used life tables and Kaplan-Meier estimates together with log-rank tests to analyse follow-up data accrued by February, 2011. Survival analyses of time to fi rst event for adults who were event-free at presentation started at the date of initial presentation and stopped at the date of the fi rst outcome event or the date of censoring, whichever occurred fi rst. Survival analyses of time to earliest recurrent event started at the date of the fi rst event (whether it occurred at initial presentation or during follow-up) and stopped at the date of the earliest recurrent outcome or the date of censoring, whichever occurred fi rst. We censored follow-up at the earliest occurrence of any of the following: death unrelated to CCM, fi rst CCM treatment (with surgical excision or stereotactic radio surgery, at the discretion of the treating physician), last available follow-up, or 5 years after initial presentation.
We stratifi ed survival analyses by mode of initial CCM presentation. We investigated the eff ect of two potential predictors: men versus women and brainstem versus other CCM primary locations. We prespecifi ed these factors on the basis of their clinical relevance and their hypothesised eff ect on outcome, as well as on the accuracy, reliability, and completeness of their ascertainment. We did univariate comparisons with the log-rank test, quantifi ed survival functions at 5 years, and did Cox regression if proportional hazards assumptions were satisfi ed. 31 We used sensitivity analyses to assess whether restriction of analyses to events defi nitely attributable to CCM aff ected our primary outcome analyses.
We did not prespecify our desired sample size, but instead we sought to identify every new defi nite CCM diagnosis over 5 years in one country (the mid-2010 population estimate of adults aged 16 years or older was 4·31 million) 32 and accrue follow-up until we had suffi cient outcome events to analyse our two potential predictors in multivariable analyses (at least 20 events to fi t a multivariable model with two covariates). We used two-tailed statistical tests (α=0·05). Analyses were done with SPSS (version 16.0), Stata (version 11.2), StatsDirect (version 2.7.8), and Confi dence Interval Analysis software (version 2.2.0).
Role of the funding source
The study sponsors had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. The corresponding author had full access to all study data and had fi nal responsibility for the decision to submit for publication.
Results
From 1999 to 2003, 139 adult residents in Scotland were newly diagnosed with at least one defi nite CCM (133 on brain MRI, fi ve at autopsy, and one after surgical excision). Of these 139 adults, 24 had multiple CCMs, 20 had associated developmental venous anomalies, two had an unrelated intracranial aneurysm, and one had an unrelated brain arteriovenous malformation. The median age of the 139 adults at the initial presentation that led to CCM diagnosis was 41 years (IQR 32-53 years) and 80 (58%) were women. The symptoms leading to CCM diagnosis were incidental (n=66, 47%), epileptic seizure (n=35, 25%), intracranial haemorrhage (n=17, 12%), and focal neurological defi cits (n=21, 15%). The primary CCM locations were lobar (n=93, 67%), brainstem (n=19, 14%), cerebellar (n=18, 13%), and deep (n=9, 6%), and there was no association between female sex and CCM location (χ² test, p=0·7).
After omitting the fi ve adults whose CCM (two brainstem and three lobar) were fi rst diagnosed inci dentally at autopsy and who did not contribute to our outcome analyses, we compared 134 adults according to their type of initial presentation (table). Adults were older at the time of incidental CCM detection than at symp tomatic initial presentations (Kruskal Wallis test, p=0·007). Adults initially presenting with intracranial haemorrhage or focal neurological defi cit were more likely to harbour brainstem CCMs (32% vs 5% with other modes of presentation, Fisher's exact test p<0·0001) and seemed to be more likely to be women, although this was not statistically signifi cant (71% vs 54%, χ² test, p=0·07).
We followed up the 134 adults with CCM who were alive at initial presentation for 1177 person-years (of 1216 potential person-years, for an overall completeness of 97%). 30 We limited our analyses to the fi rst 5 years of follow-up (although years 6 and 7 of follow-up were available for this cohort, no outcome events occurred during that time). In these analyses, the median duration of follow-up per adult was 5 years; of the 17 adults followed up for less than 5 years, 15 died within the 5-year period. Follow-up ended for these 134 adults because of censoring at last follow-up (n=97), CCM treatment (n=23, surgical excision in all cases), or death unrelated to CCM (n=14). Figure 2 describes the grouping of adults in our analyses.
Of 96 adults who initially presented incidentally or with seizures, one man and one woman had a fi rst intracranial haemorrhage (5-year risk 2·4%, 95% CI 0·0-5·7; fi gure 3). Taking together the one survivor of these fi rst intracranial haemorrhages during follow-up and the 17 adults with fi rst intracranial haemorrhage at initial presentation, four adults (all women) had a second intracranial haemorrhage (5-year risk 29·5%, 4·1-55·0; fi gure 3), which was greater than the risk of a fi rst intracranial haemorrhage (log-rank p<0·0001). Of all 23 instances of a fi rst or second haemorrhage, one was followed by death within 30 days from a fi rst intracranial haemorrhage caused by a lobar CCM (case fatality 4·3%, 95% CI 0·8-21·0).
For the primary outcome of intracranial haemorrhage and focal neurological defi cits (not including epileptic seizure) that were defi nitely or possibly related to CCM, eight of the 96 adults who initially presented incidentally or with seizures had a fi rst event (5-year risk 9·3%, 95% CI 3·1-15·4; fi gure 4). However, of the 47 adults who had, at presentation or during follow-up, a non-fatal fi rst intracranial haemorrhage or focal neurological defi cit that was defi nitely or possibly related to CCM, 17 had a second event (5-year risk 42·4%, 95% CI 26·8-58·0; fi gure 4), which was greater than the risk of a fi rst event (log-rank p<0·0001). These fi ndings were unchanged in a sensitivity analysis that excluded the events that were possibly attributable to CCM (webappendix p 4). Three of the 17 adults who had a second event had further recurrences during the follow-up period. The annual risk of a second intracranial haemorrhage or focal neurological defi cit that was defi nitely or possibly related to CCM declined during follow-up: 19·8% (95% CI 6·1-33·4) in year 1, 13·3% (0·0-26·4) in year 2, 12·0% (0·0-25·6) in year 3, 4·5% (0·0-13·5) in year 4, and 5·0% (0·0-14·8) in year 5. We could not detect any statistically signifi cant diff erence in functional outcome: after 5 years, there was no diff erence in the proportion of adults scoring 0-2 on the OHS after fi rst (89%) or second (100%) intracranial haemorrhages or focal neurological defi cits that were defi nitely or possibly related to CCM (webappendix p 5).
We explored our two prespecifi ed potential predictors of a second event for the 47 adults who had a fi rst intracranial haemorrhage or focal neurological defi cit that was defi nitely or possibly attributable to CCM. The risk of a second event was signifi cantly higher for women than men (fi gure 5; p=0•01). In a post-hoc analysis of the infl uence of sex on recurrent intracranial haemorrhage alone, we found that all four recurrent haemorrhages occurred in women but that the diff erence in risk between men and women was not statistically signifi cant (p=0·29). We did not identify a greater risk for brainstem CCM compared with CCM in other locations (p=0•17; webappendix p 6). We were unable to do Cox regression involving both sex and CCM location because proportional hazards assumptions were not fulfi lled (webappendix p 7). 31 We assessed the potential for, but could not confi rm, confounding between sex and CCM location among these 47 adults: of 12 women with brainstem CCM, seven (58%) had outcome events; of two men with brainstem CCM, one (50%) had an outcome event; of 20 women with non-brainstem CCM, nine (45%) had outcome events; and of 13 men with non-brainstem CCM, none (0%) had an outcome event. Multiple CCMs (vs solitary CCM; p=0•7) and the presence of an associated developmental venous anomaly (vs the absence of such an anomaly; p=0•3) did not predict a second event during follow-up (data not shown).
Discussion
In this prospective, population-based study of adults with CCM, the 5-year risk of a fi rst intracranial haemorrhage was lower than the risk of recurrence. The diff erence between the risks of fi rst and recurrent events was also evident for the primary composite endpoint, for which the annual risk of intracranial haemorrhage or focal neurological defi cit defi nitely or possibly related to CCM was higher for women than men and declined signifi cantly over 5 years. We confi rmed our prespecifi ed hypothesis that sex infl uences the risk of recurrence.
In this study, we minimised several potential sources of bias: selection bias, by using a population-based design restricted to newly diagnosed cases; detection and misclassifi cation biases, by using strict diagnostic criteria and outcome defi nitions; 11, 13 information bias, by using prospective follow-up, which attained 97% completeness over 5 years; and bias in outcome assessment, by masking assessors to potential prognostic features. [33] [34] [35] We followed up each adult for a median of 5 years and quantifi ed outcomes at 5 years to facilitate comparison with future studies; 13 we could have quantifi ed outcomes over 7 years, but no outcome events occurred between 5 and 7 years, which further underscores our fi nding of a diminishing annual rate of recurrence over time.
Despite identifying all incident CCM diagnoses in an adult population over 5 years and assessing the cohort for 5 years, the precision of our estimates could be improved, and we have addressed this by recently identifying a second CCM cohort, results from which will be reported in the future. We used clinical information and the uncertainties of symptom attribution to CCM inherent in everyday clinical practice to enhance the generalisability of our fi ndings, [33] [34] [35] but we might have missed some events by not relying on scheduled study visits. Anecdotally, CCM haemorrhage can present with epileptic seizure alone, so we might have underestimated CCM haemorrhage rates, but brain imaging is not used to investigate every seizure in clinical practice. Survival analyses include an assumption that censoring is not informative, but treatment might be related to a patient's future prognosis. In some of our comparisons with log-rank tests, a few adults contributed diff erent periods of their follow-up time to the two groups being compared. The tendency of clinicians to investigate young, normotensive patients with intra cerebral haemor rhage could have led to bias in CCM detection in favour of these groups. 36 The classi fi cation of presenting and outcome events as either intracranial haemorrhage or focal neurological defi cit depends on the availability and use of timely imaging of the appropriate modality, which varies between health services. To facilitate comparisons with other cohorts, and because both of these clinical events are of comparable clinical eff ect and probably share the same pathophysiology, we amalgamated them in a composite outcome, but work remains to be done on the inter-rater and intra-rater reliability of the classifi cation of these outcomes. 13 The diff erence in risk of recurrence by sex might be explained by reporting bias but, as has been found in other contexts, 37 we think a true diff erence is a more likely explanation, which might also have caused the possible preponderance of women initially presenting with intracranial haemorrhage or focal neurological defi cit. Various explanations for this fi nding involve biologically plausible mechanisms related to the hormonal responsiveness of CCM, due to pregnancy, contraception, or hormone replacement therapy. 5, 16, 20, 38 Most published studies of CCM prognosis have been small, single-centre case series that were potentially subject to selection bias, which might explain some of the diff erences between these studies (panel). In some studies, lifetime event rates have been calculated retrospectively assuming CCM presence since birth, but we did not include these studies in our systematic review or use this technique because CCMs are known to occur de novo and might not be congenital. 9 Most published studies have combined fi rst and recurrent events and calculated annualised risks without actuarial analysis
Panel: Research in context
Systematic review
We used electronic strategies (webappendix p 1) to search for journal articles, published before Dec 1, 2011, and indexed in OVID Medline and Embase, that described original studies of more than 20 adults with cerebral cavernous malformations (CCMs) and enumerated symptomatic intracranial haemorrhages during a quantifi ed period of follow-up. We systematically compared these studies with our characteristics of an ideal study of CCM prognosis (webappendix pp 2-3). [33] [34] [35] We extracted the published annualised symptomatic intracranial haemorrhage rate from each study (or calculated it on the basis of the number of symptomatic intracranial haemorrhages occurring during its total person-years of follow-up after CCM diagnosis). We also extracted the corresponding 95% CI if published (or calculated the 95% CI around this incidence rate with Confi dence Interval Analysis software, if the necessary data had been published), and stratifi ed our presentation of these rates in the 14 included studies by mode of initial CCM clinical presentation (fi gure 1). 3, 5, 12, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 
Interpretation
Published studies have quantifi ed variable outcomes for adults with CCM according to sex, mode of initial presentation, and CCM location (fi gure 1). To our knowledge, this is the fi rst cohort study of CCM that is prospective, is population-based, and adheres to standards recommended for prognosis research. [11] [12] [13] [33] [34] [35] We show that the risk of recurrent intracranial haemorrhage is an order of magnitude greater than the risk of a fi rst haemorrhage, and that the risk of a recurrent intracranial haemorrhage or focal neurological defi cit is greater for women than men and declines over time.
during follow-up, 5, 12, 18, 19, 25 which masked the phenomenon of diminishing event rate and temporal clustering of CCM haemorrhages. 21, 24 Our fi ndings are important for clinical practice, in which patients and their clinicians have to make decisions about CCM treatment on the basis of the untreated clinical course of CCM and without the benefi t of randomised controlled trials. We have shown that the risk of a fi rst-ever intracranial haemorrhage is low; functional impairment from haemorrhage is mild at initial presentation, 26 and from our fi ndings it seems that further recovery occurs during follow-up and 30-day case fatality is low. Although the risk of recurrence is higher than the risk of a fi rst event, especially for women, the risk of recurrence seems to decline over time. This decline provides some reassurance for patients as time passes without CCM treatment after a haemorrhage, and suggests that decision making about CCM treatment in clinical practice (and in future randomised controlled trials) might not need to be compared with the untreated clinical course in the long term when event rates may be very low.
We, and others, should continue observation of these patients over their lifetimes to confi rm the apparent decline in risk of recurrent intracranial haemorrhage or focal neurological defi cit over time. 21, 24 Greater precision is also needed: the size of our cohort should double with the addition of adults diagnosed from 2006 to 2010, and we are planning an individual patient data meta-analysis with other cohorts. These further studies might improve the precision of our estimates and allow confi rmation of the predictors that we have identifi ed, assessment of other potential predictors, and investigation of why women are at a higher risk of recurrence than men. 34 The 5-year event rates and the declining risk of recurrence that we have observed will help in the design of randomised controlled trials, which hitherto have not been conducted for CCM.
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